Publication | Open Access

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials

Propensity Score-adjusted AnalysisGastrointestinal OncologyMedicineCancer ManagementClinical TrialsColorectal CancerMetastatic Colorectal CancerPharmacotherapyRandomized Clinical TrialsCancer TreatmentOncologyRadiation OncologyCancer ResearchHealth Sciences